Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JNCI Cancer Spectr
Autors principals: Pogue-Geile, Katherine L, Song, Nan, Serie, Daniel J, Wang, Ying, Gavin, Patrick G, Kim, Rim S, Tanaka, Noriko, Fumagalli, Debora, Taniyama, Yusuke, Li, Zhuo, Rastogi, Priya, Swain, Sandra M, Mamounas, Eleftherios P, Geyer, Charles E, Wolmark, Norman, Lucas, Peter C, Paik, Soonmyung, Thompson, E Aubrey
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674704/
https://ncbi.nlm.nih.gov/pubmed/33241186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa058
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars